Pediatr. praxi. 2022;23(6):397-401 | DOI: 10.36290/ped.2022.071

Primary disorders of monoamine neurotransmitter metabolism in clinical practice

MUDr. Martin Macháček, doc. MUDr. Hana Ošlejšková, Ph.D.
Klinika dětské neurologie LF MU a FN Brno

Primary disorders of monoamine neurotransmitters are a group of rare inherited neurometabolic diseases. Dominant signs of these disorders are the appearance of first symptoms in early childhood, polymorph symptomatology with variable prognosis, difficult definitive diagnosis, and in most cases, absence of causal therapy. Many patients worldwide stay undiagnosed since there is a lack of sufficient knowledge among health professionals. The authors tend to familiarize health professionals with the most important representatives of these disorders.

Keywords: monoamine neurotransmitters, tetrahydrobiopterin, psychomotor retardation, dystonia, AADC-D, gene therapy.

Accepted: November 16, 2022; Published: November 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Macháček M, Ošlejšková H. Primary disorders of monoamine neurotransmitter metabolism in clinical practice. Pediatr. praxi. 2022;23(6):397-401. doi: 10.36290/ped.2022.071.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brennenstuhl H, Jung-Klawitter S, Assmann B, et al. Inherited Disorders of Neurotransmitters: Classification and Practical Approaches for Diagnosis and Treatment. Neuropediatrics. 2019;50(1):2-14. Go to original source... Go to PubMed...
    2. Ng J, Papandreou A, Heales SJ, et al. Monoamine neurotransmitter disorders - clinical advances and future perspectives. Nat Rev Neurol. 2015;11(10):567-584. Go to original source... Go to PubMed...
    3. Szentiványi K, Hansíková H, Krijt J, et al. Poruchy metabolizmu biogenních aminů v dětském věku a možnosti jejich diagnostiky. Cesk Slov Neurol N. 2010;73/106(6):656-662.
    4. Pearson TS, Pons R, Ghaoui R, et al. Genetic mimics of cerebral palsy. Mov Disord. May 2009;34(5):625-636. Go to original source... Go to PubMed...
    5. DeFilippis M, Wagner KD. Treatment of Autism Spectrum Disorder in Children and Adolescents. Psychopharmacol Bull. 2016;46(2):18-41. Go to PubMed...
    6. Himmelreich N, Montioli R, Bertoldi M, et al. Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook. Mol Genet Metab. 2019;127(1):12-22. Go to original source... Go to PubMed...
    7. Wassenberg T, Molero-Luis M, Jeltsch K, et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. Orphanet J Rare Dis. 2017;12(1):12. Go to original source... Go to PubMed...
    8. Tai CH, Lee NC, Chien YH, et al. Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol Ther. 2022;30(2):509-518. Go to original source... Go to PubMed...
    9. Chien YH, Chen PW, Lee NC, et al. 3-O-methyldopa levels in newborns: Result of newborn screening for aromatic l-amino-acid decarboxylase deficiency. Mol Genet Metab. 2016;118(4):259-263. Go to original source... Go to PubMed...
    10. Lee NC, Chien YH, Hwu WL. A review of aromatic l -amino acid decarboxylase (AADC) deficiency in Taiwan. Am J Med Genet. 2019;181(2):226-229. Go to original source... Go to PubMed...
    11. García-Cazorla À, Artuch R. Neurotransmitter disorders. In: Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease. Elsevier; 2020:917-929. Go to original source...
    12. Furukawa Y. GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia. In: Adam MP, Everman DB, Mirzaa GM, et al. GeneReviews®. University of Washington, Seattle; 1993.
    13. Furukawa Y, Kish S. Tyrosine Hydroxylase Deficiency. In: Adam MP, Everman DB, Mirzaa GM, et al. GeneReviews®. University of Washington, Seattle; 1993.
    14. Friedman J. Sepiapterin Reductase Deficiency. In: Adam MP, Everman DB, Mirzaa GM, et al. GeneReviews®. University of Washington, Seattle; 1993.
    15. Szentiványi K, Hansíková H, Krijt J, et al. Novel Mutations in the Tyrosine Hydroxylase Gene in the First Czech Patient with Tyrosine Hydroxylase Deficiency. Prague Med Rep. 2015;113(2):136-146. Go to original source... Go to PubMed...
    16. Szentiványi K, Hansíková H, Krijt J, et al. The importance of biogenic amines metabolites determination in cerebrospinal fluid by high performance liquid chromatogramy in the diagnostics of pediatric neurotransmitter disorders. Klin. Biochem. Metab. 2011;19(40)3:155-161.
    17. Pešková K, Chrastina P, Bártl J, et al. Novorozenecký screening dědičných metabolických poruch v České republice. Čes-slov Pediat. 2018;73(6):390-394.
    18. van Spronsen FJ, Blau N, Harding C, et al. Phenylketonuria. Nat Rev Dis Primers. 2021;7(1):36. Go to original source... Go to PubMed...
    19. Opladen T, López-Laso E, Cortès-Saladelafont E, et al. Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. Orphanet J Rare Dis. 2020;15:126. Go to original source... Go to PubMed...
    20. van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet Journal of Rare Diseases. 2017;12(1):162. Go to original source... Go to PubMed...
    21. Kojima K, Nakajima T, Taga N, et al. Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency. Brain. 2019;142(2):322-333. Go to original source... Go to PubMed...
    22. EMA. Upstaza. European Medicines Agency. Published April 13, 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/upstaza.

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.